Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Development of thyroid carcinoma during treatment with pembrolizumab in a lung cancer patient.

Gorospe L, García-Gómez-Muriel I, Pian-Arias HG, Gómez-Ramírez J, Rioja-Martín ME, Olmedo-García ME, Garrido-López P, Muñoz-Molina GM, Mezquita L.

Ann Thorac Surg. 2019 Dec 14. pii: S0003-4975(19)31873-9. doi: 10.1016/j.athoracsur.2019.10.059. [Epub ahead of print]

PMID:
31846639
2.

Cross-cultural examination of the Big Five Personality Trait Short Questionnaire: Measurement invariance testing and associations with mental health.

Mezquita L, Bravo AJ, Morizot J, Pilatti A, Pearson MR, Ibáñez MI, Ortet G, Cross-Cultural Addictions Study Team.

PLoS One. 2019 Dec 17;14(12):e0226223. doi: 10.1371/journal.pone.0226223. eCollection 2019.

3.

Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B.

J Thorac Oncol. 2019 Dec 13. pii: S1556-0864(19)33716-5. doi: 10.1016/j.jtho.2019.11.024. [Epub ahead of print]

PMID:
31843682
4.

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G.

Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0643-y. [Epub ahead of print]

PMID:
31761899
5.

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.

Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, Caramella C, Deutsch E, Grimaldi S, Adam J, Ammari S, Planchard D, Leboulleux S, Besse B.

Eur J Nucl Med Mol Imaging. 2019 Nov 21. doi: 10.1007/s00259-019-04615-x. [Epub ahead of print]

PMID:
31754795
6.

Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer.

Lavaud P, Besse B, de Baere T, Deschamps F, Mussot S, Le Pechoux C, Caramella C, Mercier O, Mezquita L, Botticella A, Pradere P, Adam J, Planchard D, Tselikas L.

Cardiovasc Intervent Radiol. 2020 Jan;43(1):168. doi: 10.1007/s00270-019-02370-y.

PMID:
31690981
7.

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.

Botticella A, Mezquita L, Le Pechoux C, Planchard D.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530. doi: 10.1177/1753466619885530.

8.

Depressive symptoms, ruminative thinking, marijuana use motives, and marijuana outcomes: A multiple mediation model among college students in five countries.

Bravo AJ, Sotelo M, Pilatti A, Mezquita L, Read JP; Cross-Cultural Addictions Study Team.

Drug Alcohol Depend. 2019 Nov 1;204:107558. doi: 10.1016/j.drugalcdep.2019.107558. Epub 2019 Sep 16.

PMID:
31586807
9.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.

PMID:
31585938
10.

Letter to the Editor about Sorich et al.

Mezquita L, Auclin E, Besse B.

J Thorac Oncol. 2019 Sep;14(9):e209. doi: 10.1016/j.jtho.2019.05.022. No abstract available.

PMID:
31445741
11.

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.

Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honoré A, Lecluse Y, Queffelec P, NgoCamus M, Nicotra C, Remon J, Lacroix L, Planchard D, Friboulet L, Besse B, Farace F.

Clin Cancer Res. 2019 Nov 15;25(22):6671-6682. doi: 10.1158/1078-0432.CCR-19-1176. Epub 2019 Aug 22.

PMID:
31439588
12.

Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?

Rassy E, Mezquita L, Remon J, Besse B.

Immunotherapy. 2019 Sep;11(13):1149-1160. doi: 10.2217/imt-2019-0071. Epub 2019 Jul 30.

PMID:
31361172
13.

Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.

Leclerc M, Mezquita L, Guillebot De Nerville G, Tihy I, Malenica I, Chouaib S, Mami-Chouaib F.

Front Immunol. 2019 Jul 3;10:1505. doi: 10.3389/fimmu.2019.01505. eCollection 2019. Review.

14.

Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC.

Benitez JC, Mezquita L, Colle R, Tselikas L, Botticella A, Caramella C, Besse B.

J Thorac Oncol. 2019 Oct;14(10):e215-e216. doi: 10.1016/j.jtho.2019.07.001. Epub 2019 Jul 11. No abstract available.

PMID:
31302233
15.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.

PMID:
31203193
16.

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients.

Mezquita L, Benito A, Ruano-Raviña A, Zamora J, Olmedo ME, Reguera P, Madariaga A, Villamayor M, Cortez SP, Gorospe L, Santón A, Mayoralas S, Hernanz R, Cabañero A, Auclin E, Carrato A, Garrido P.

Clin Lung Cancer. 2019 Jul;20(4):305-312.e3. doi: 10.1016/j.cllc.2019.04.009. Epub 2019 May 3.

PMID:
31151782
17.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
18.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.

Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B.

J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.

PMID:
31108248
19.

Negative marijuana-related consequences among college students in five countries: measurement invariance of the Brief Marijuana Consequences Questionnaire.

Bravo AJ, Pearson MR, Pilatti A, Mezquita L; Cross-Cultural Addictions Study Team.

Addiction. 2019 Oct;114(10):1854-1865. doi: 10.1111/add.14646. Epub 2019 Jul 8.

PMID:
31066108
20.

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR.

Madic J, Jovelet C, Lopez J, André B, Fatien J, Miran I, Honoré A, Mezquita L, Besse B, Lacroix L, Droniou M.

Oncotarget. 2019 Feb 12;10(13):1345. doi: 10.18632/oncotarget.26686. eCollection 2019 Feb 12.

21.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16.

PMID:
30780002
22.

Cross-cultural examination of negative alcohol-related consequences: Measurement invariance of the Young Adult Alcohol Consequences Questionnaire in Spain, Argentina, and USA.

Bravo AJ, Pilatti A, Pearson MR, Read JP, Mezquita L, Ibáñez MI, Ortet G.

Psychol Assess. 2019 May;31(5):631-642. doi: 10.1037/pas0000689. Epub 2019 Jan 21.

PMID:
30667265
23.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N.

Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14.

PMID:
30648633
24.

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR.

Madic J, Jovelet C, Lopez J, André B, Fatien J, Miran I, Honoré A, Mezquita L, Besse B, Lacroix L, Droniou M.

Oncotarget. 2018 Dec 21;9(100):37393-37406. doi: 10.18632/oncotarget.26446. eCollection 2018 Dec 21. Erratum in: Oncotarget. 2019 Feb 12;10(13):1345. Lezquita, Laura [corrected to Mezquita, Laura].

25.

Recent Stressful Life Events (SLE) and Adolescent Mental Health: Initial Validation of the LEIA, a New Checklist for SLE Assessment According to Their Severity, Interpersonal, and Dependent Nature.

Moya-Higueras J, Cuevas A, Marques-Feixa L, Mezquita L, Mayoral M, Fañanás L, Ortet G, Ibáñez MI.

Assessment. 2018 Dec 12:1073191118817648. doi: 10.1177/1073191118817648. [Epub ahead of print]

PMID:
30539643
26.

Contribution of the Five Factors of Personality and Peers on Adolescent Alcohol Use: A Cross-National Study.

Gallego S, Mezquita L, Moya-Higueras J, Ortet G, Ibáñez MI.

Span J Psychol. 2018 Nov 27;21:E58. doi: 10.1017/sjp.2018.63.

PMID:
30477601
27.

Safety of osimertinib in EGFR-mutated non-small cell lung cancer.

Mezquita L, Varga A, Planchard D.

Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248. doi: 10.1080/14740338.2018.1549222. Epub 2018 Dec 5. Review.

PMID:
30457891
28.

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.

Schernberg A, Mezquita L, Boros A, Botticella A, Caramella C, Besse B, Escande A, Planchard D, Le Péchoux C, Deutsch E.

PLoS One. 2018 Oct 10;13(10):e0204490. doi: 10.1371/journal.pone.0204490. eCollection 2018.

29.

Cross-cultural examination of different personality pathways to alcohol use and misuse in emerging adulthood.

Mezquita L, Bravo AJ, Ortet G, Pilatti A, Pearson MR, Ibáñez MI.

Drug Alcohol Depend. 2018 Nov 1;192:193-200. doi: 10.1016/j.drugalcdep.2018.08.004. Epub 2018 Sep 18.

PMID:
30268069
30.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

31.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
32.

Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab.

Cabañero A, Gorospe L, Olmedo ME, Mezquita L.

Arch Bronconeumol. 2019 Mar;55(3):168-169. doi: 10.1016/j.arbres.2018.06.005. Epub 2018 Jul 14. English, Spanish. No abstract available.

33.

Durvalumab for the treatment of non-small cell lung cancer.

Mezquita L, Planchard D.

Expert Rev Respir Med. 2018 Aug;12(8):627-639. doi: 10.1080/17476348.2018.1494575. Epub 2018 Jul 9. Review.

PMID:
29958099
34.

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Remon J, Mezquita L, Corral J, Vilariño N, Reguart N.

J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52. Review.

35.

Nivolumab-induced pneumonitis complicated by cyst formation.

Gorospe L, Ayala-Carbonero AM, Olmedo-García ME, Gómez-Rueda A, Palka M, Mezquita L, Garrido-López P.

Lung Cancer. 2018 Aug;122:258-259. doi: 10.1016/j.lungcan.2018.06.012. Epub 2018 Jun 11. No abstract available.

PMID:
29914770
36.

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Geraud A, Mezquita L, Bigot F, Caramella C, Planchard D, Le Pechoux C, Besse B.

J Thorac Oncol. 2018 Nov;13(11):e215-e217. doi: 10.1016/j.jtho.2018.05.033. Epub 2018 Jun 6. No abstract available.

37.

Impulsivity-related traits, college alcohol beliefs, and alcohol outcomes: Examination of a prospective multiple mediation model among college students in Spain, Argentina, and USA.

Bravo AJ, Pearson MR, Pilatti A, Read JP, Mezquita L, Ibáñez MI, Ortet G.

Addict Behav. 2018 Jun;81:125-133. doi: 10.1016/j.addbeh.2018.02.009. Epub 2018 Feb 6.

PMID:
29454812
38.

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Mezquita L, Planchard D.

Cancer Manag Res. 2018 Jan 18;10:123-130. doi: 10.2147/CMAR.S129963. eCollection 2018. Review.

39.

Development and Validation of the Marijuana Motives Measure Short Form.

Mezquita L, Ruiz-Valero L, Martínez-Gómez N, Ibáñez MI, Ortet G.

Adicciones. 2019 Apr 1;31(2):106-116. doi: 10.20882/adicciones.979. English, Spanish.

40.

Development and validation of the alcohol Expectancy Questionnaire Short Form (EQ-SF).

Mezquita L, Camacho L, Suso-Ribera C, Ortet G, Ibáñez MI.

Adicciones. 2018 Jan 15;30(4):271-281. doi: 10.20882/adicciones.920. English, Spanish.

41.

Progress in the Management of Advanced Thoracic Malignancies in 2017.

Ferrara R, Mezquita L, Besse B.

J Thorac Oncol. 2018 Mar;13(3):301-322. doi: 10.1016/j.jtho.2018.01.002. Epub 2018 Jan 11. Review.

42.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

43.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
44.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
45.

Durvalumab in non-small-cell lung cancer patients: current developments.

Mezquita L, Planchard D.

Future Oncol. 2018 Feb;14(3):205-222. doi: 10.2217/fon-2017-0373. Epub 2017 Nov 15. Review.

PMID:
29140105
46.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
47.

Cross-cultural examination of college drinking culture in Spain, Argentina, and USA: Measurement invariance testing of the College Life Alcohol Salience Scale.

Bravo AJ, Pearson MR, Pilatti A, Read JP, Mezquita L, Ibáñez MI, Ortet G.

Drug Alcohol Depend. 2017 Nov 1;180:349-355. doi: 10.1016/j.drugalcdep.2017.08.016. Epub 2017 Sep 9.

PMID:
28950241
48.

Effects of Social Attitude Change on Smoking Heritability.

Mezquita L, Sánchez-Romera JF, Ibáñez MI, Morosoli JJ, Colodro-Conde L, Ortet G, Ordoñana JR.

Behav Genet. 2018 Jan;48(1):12-21. doi: 10.1007/s10519-017-9871-1. Epub 2017 Sep 25.

49.

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B.

Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24. Review.

50.

Depressive symptoms, ruminative thinking, drinking motives, and alcohol outcomes: A multiple mediation model among college students in three countries.

Bravo AJ, Pilatti A, Pearson MR, Mezquita L, Ibáñez MI, Ortet G.

Addict Behav. 2018 Jan;76:319-327. doi: 10.1016/j.addbeh.2017.08.028. Epub 2017 Aug 31.

PMID:
28889061

Supplemental Content

Loading ...
Support Center